ArticleJACC. Case reports2026
Pulmonary Artery Pressure Sensor-Guided Therapy for Cardiac AL Amyloidosis in a Young Multiple Myeloma Patient.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVolume assessment in cardiac amyloid light chain (AL) amyloidosis is challenging during high-dose chemotherapy and autologous stem cell transplantation (SCT), as clinical findings and body weight may not accurately reflect intravascular congestion. CASE SUMMARY: A 45-year-old man with multiple myeloma, nephrotic syndrome, and cardiac AL amyloidosis developed marked volume fluctuations during induction therapy. Before SCT, an implantable pulmonary artery pressure (PAP) sensor was placed to guide diuretics, targeting a diastolic PAP of 22 mm Hg. During the peritransplant period, remote PAP monitoring enabled individualized diuretic titration despite mucositis, gastrointestinal losses, transfusions, neutropenic fever, delirium, and weight variation. He completed SCT without heart failure decompensation and achieved complete hematologic remission. DISCUSSION: This case highlights the value of PAP-guided management in complex cardio-oncology patients with dynamic hemodynamics. TAKE-HOME MESSAGES: In cardiac AL amyloidosis, invasive hemodynamic monitoring may outperform clinical assessment. PAP-guided management may be useful during SCT when risks of congestion and hypovolemia coexist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.